Non-association of Estrogen Receptor Genotypes with Bone Mineral Density and Bone Turnover in Korean Pre-, Peri-, and Postmenopausal Women

Although it is well established that estrogen deficiencycauses osteoporosis among the postmenopausalwomen, the involvement of estrogen receptor (ER) in itspathogenesis still remains uncertain. In the presentstudy, we have generated rats harboring a dominantnegative ERa, which inhibits the actions of not only ERabut also recently identified ERb. Contrary to our expectation,the bone mineral density (BMD) of the resultingtransgenic female rats was maintained at the same levelwith that of the wild-type littermates when sham-operated.In addition, ovariectomy-induced bone loss wasobserved almost equally in both groups. Strikingly, however,the BMD of the transgenic female rats, after ovariectomized,remained decreased even if 17b-estradiol(E2) was administrated, whereas, in contrast, the decreaseof littermate BMD was completely prevented byE2. Moreover, bone histomorphometrical analysis ofovariectomized transgenic rats revealed that the higherrates of bone turnover still remained after treatmentwith E2. These results demonstrate that the preventionfrom the ovariectomy-induced bone loss by estrogen ismediated by ER pathways and that the maintenanceof BMD before ovariectomy might be compensatedby other mechanisms distinct from ERa and ERbpathways.

Download Full-text

Retraction Note: Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis

Clinical Rheumatology ◽

10.1007/s10067-021-05788-3 ◽

2021 ◽

Author(s):

Jun Iwamoto ◽

Tsuyoshi Takeda ◽

Yoshihiro Sato ◽

Mitsuyoshi Uzawa

Keyword(s):

Bone Mineral Density ◽

Bone Turnover ◽

Postmenopausal Women ◽

Bone Mineral ◽

Lumbar Bone Mineral Density ◽

Mineral Density

Download Full-text

Association between Baseline Values of Bone Turnover Markers and Bone Mineral Density and Their Response to Raloxifene Treatment in Japanese Postmenopausal Women with Osteoporosis

Endocrine Journal ◽

10.1507/endocrj.k07-078 ◽

2008 ◽

Vol 55 (1) ◽

pp. 41-48 ◽

Cited By ~ 2

Author(s):

Takafumi MAJIMA ◽

Akira SHIMATSU ◽

Yasato KOMATSU ◽

Noriko SATOH ◽

Atsushi FUKAO ◽

...

Keyword(s):

Bone Mineral Density ◽

Bone Turnover ◽

Postmenopausal Women ◽

Bone Mineral ◽

Bone Turnover Markers ◽

Mineral Density ◽

Baseline Values ◽

Turnover Markers

Download Full-text

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

Journal of Osteoporosis ◽

10.1155/2016/8738959 ◽

2016 ◽

Vol 2016 ◽

pp. 1-6 ◽

Cited By ~ 4

Author(s):

A. Sánchez ◽

L. R. Brun ◽

H. Salerni ◽

P. R. Costanzo ◽

D. González ◽

...

Keyword(s):

Bone Mineral Density ◽

Bone Turnover ◽

Postmenopausal Women ◽

Bone Mineral ◽

Bone Turnover Markers ◽

Control Group ◽

Bone Resorption Marker ◽

Similar Response ◽

Mineral Density ◽

Turnover Markers

The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab.Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.

Download Full-text

Bone Turnover and Bone Mineral Density Are Independently Related to Selenium Status in Healthy Euthyroid Postmenopausal Women

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2012-2121 ◽

2012 ◽

Vol 97 (11) ◽

pp. 4061-4070 ◽

Cited By ~ 40

Author(s):

Antonia Hoeg ◽

Apostolos Gogakos ◽

Elaine Murphy ◽

Sandra Mueller ◽

Josef Köhrle ◽

...

Keyword(s):

Bone Mineral Density ◽

Bone Turnover ◽

Postmenopausal Women ◽

Bone Mineral ◽

Selenoprotein P ◽

Selenium Status ◽

Mineral Density ◽

Thyroid Status ◽

Hip Bmd

Context: Selenium status may have direct effects on bone and indirect effects through changes in thyroid hormone sensitivity. Objective: We hypothesized that variation in selenium status in healthy euthyroid postmenopausal women is associated with differences in bone turnover, bone mineral density (BMD) and fracture susceptibility. Design: The Osteoporosis and Ultrasound Study (OPUS) is a 6-yr prospective study of fracture-related factors. Setting: The study was comprised of a population-based cohort from five European cities. Participants: A total of 2374 postmenopausal women participated. Subjects with thyroid disease and nonthyroidal illness and those receiving drugs affecting thyroid status or bone metabolism were excluded, leaving a study population of 1144. Interventions: There were no interventions. Main Outcome Measures: We measured selenium (micrograms per liter); selenoprotein P (milligrams per liter); free T4 (picomoles per liter); free T3 (picomoles per liter); TSH (milliunits per liter); bone turnover markers; BMD; and vertebral, hip, and nonvertebral fractures. Results: Higher selenium levels were associated with higher hip BMD at study entry (β = 0.072, P = 0.004) and lower levels of bone formation (osteocalcin: β = −0.101, P < 0.001; procollagen type 1 N-terminal propeptide: β = −0.074, P = 0.013) and resorption markers (C-telopeptide of type 1 collagen: β = −0.058, P = 0.050; N-telopeptide of type 1 collagen: β = −0.095, P = 0.002). Higher selenoprotein P was associated with higher hip (β = 0.113, P < 0.001) and lumbar spine BMD (β = 0.088, P = 0.003) at study entry, higher hip BMD after the 6-yr follow-up (β = 0.106, P = 0.001) and lower osteocalcin (β = −0.077, P = 0.009), C-telopeptide of type 1 collagen (β = −0.075, P = 0.012), and N-telopeptide of type 1 collagen (β = −0.110, P < 0.001). Conclusion: Selenium status is inversely related to bone turnover and positively correlated with BMD in healthy euthyroid postmenopausal women independent of thyroid status.

Download Full-text